Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer - PubMed (original) (raw)
Clinical Trial
. 2001 Jul;7(7):1894-900.
Affiliations
- PMID: 11448902
Clinical Trial
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer
R A Sharma et al. Clin Cancer Res. 2001 Jul.
Abstract
Curcuma spp. extracts, particularly the dietary polyphenol curcumin, prevent colon cancer in rodents. In view of the sparse information on the pharmacodynamics and pharmacokinetics of curcumin in humans, a dose-escalation pilot study of a novel standardized Curcuma extract in proprietary capsule form was performed at doses between 440 and 2200 mg/day, containing 36-180 mg of curcumin. Fifteen patients with advanced colorectal cancer refractory to standard chemotherapies received Curcuma extract daily for up to 4 months. Activity of glutathione S-transferase and levels of a DNA adduct (M(1)G) formed by malondialdehyde, a product of lipid peroxidation and prostaglandin biosynthesis, were measured in patients' blood cells. Oral Curcuma extract was well tolerated, and dose-limiting toxicity was not observed. Neither curcumin nor its metabolites were detected in blood or urine, but curcumin was recovered from feces. Curcumin sulfate was identified in the feces of one patient. Ingestion of 440 mg of Curcuma extract for 29 days was accompanied by a 59% decrease in lymphocytic glutathione S-transferase activity. At higher dose levels, this effect was not observed. Leukocytic M(1)G levels were constant within each patient and unaffected by treatment. Radiologically stable disease was demonstrated in five patients for 2-4 months of treatment. The results suggest that (a) Curcuma extract can be administered safely to patients at doses of up to 2.2 g daily, equivalent to 180 mg of curcumin; (b) curcumin has low oral bioavailability in humans and may undergo intestinal metabolism; and (c) larger clinical trials of Curcuma extract are merited.
Similar articles
- Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance.
Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Sharma RA, et al. Clin Cancer Res. 2004 Oct 15;10(20):6847-54. doi: 10.1158/1078-0432.CCR-04-0744. Clin Cancer Res. 2004. PMID: 15501961 Clinical Trial. - Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents.
Plummer SM, Hill KA, Festing MF, Steward WP, Gescher AJ, Sharma RA. Plummer SM, et al. Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1295-9. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11751448 Clinical Trial. - Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.
Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ. Garcea G, et al. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):120-5. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 15668484 Clinical Trial. - Curcuma as a functional food in the control of cancer and inflammation.
Schaffer M, Schaffer PM, Zidan J, Bar Sela G. Schaffer M, et al. Curr Opin Clin Nutr Metab Care. 2011 Nov;14(6):588-97. doi: 10.1097/MCO.0b013e32834bfe94. Curr Opin Clin Nutr Metab Care. 2011. PMID: 21986478 Review.
Cited by
- Anti-proliferative activities of Byrsocarpus coccineus Schum. and Thonn. (Connaraceae) using ovarian cancer cell lines.
Ukwade CE, Ebuehi OAT, Adisa RA, Singh SK, Singh R. Ukwade CE, et al. J Ovarian Res. 2020 Jul 21;13(1):83. doi: 10.1186/s13048-020-00679-8. J Ovarian Res. 2020. PMID: 32693841 Free PMC article. - Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress.
Lin J, Tang Y, Kang Q, Feng Y, Chen A. Lin J, et al. Br J Pharmacol. 2012 Aug;166(8):2212-27. doi: 10.1111/j.1476-5381.2012.01910.x. Br J Pharmacol. 2012. PMID: 22352842 Free PMC article. - Curcumin suppresses NTHi-induced CXCL5 expression via inhibition of positive IKKβ pathway and up-regulation of negative MKP-1 pathway.
Konduru AS, Lee BC, Li JD. Konduru AS, et al. Sci Rep. 2016 Aug 19;6:31695. doi: 10.1038/srep31695. Sci Rep. 2016. PMID: 27538525 Free PMC article. - Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence.
Kotecha R, Takami A, Espinoza JL. Kotecha R, et al. Oncotarget. 2016 Aug 9;7(32):52517-52529. doi: 10.18632/oncotarget.9593. Oncotarget. 2016. PMID: 27232756 Free PMC article. Review. - A comprehensive update on the potential of curcumin to enhance chemosensitivity in colorectal cancer.
Shadnoush M, Momenan M, Seidel V, Tierling S, Fatemi N, Nazemalhosseini-Mojarad E, Norooz MT, Cheraghpour M. Shadnoush M, et al. Pharmacol Rep. 2024 Sep 20. doi: 10.1007/s43440-024-00652-y. Online ahead of print. Pharmacol Rep. 2024. PMID: 39304638 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous